Euroapi (EAPI) Resumen de Acciones
Euroapi S.A. desarrolla, fabrica, comercializa y distribuye principios activos farmacéuticos e intermedios utilizados en la formulación de medicamentos de uso humano y veterinario. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
EAPI Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Euroapi S.A.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | €1.50 |
| Máximo en las últimas 52 semanas | €3.57 |
| Mínimo de 52 semanas | €1.22 |
| Beta | 0.96 |
| Cambio en 1 mes | 17.37% |
| Variación en 3 meses | -30.04% |
| Cambio de 1 año | -44.24% |
| Variación en 3 años | -85.21% |
| Variación en 5 años | n/a |
| Variación desde la OPV | -88.90% |
Noticias y actualizaciones recientes
Actualización de narrativa • May 10
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Euroapi's analyst price target has shifted lower from about €3.08 to €2.00, with analysts pointing to Deutsche Bank's recent cut in its target to €1, along with updated views on revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts may see the lower price target range, now clustering around €1 to €2, as setting a more conservative bar for execution, which can reduce the risk of further valuation resets if expectations are now better aligned with current fundamentals.
Actualización de narrativa • Apr 22
EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings
Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.
Actualización de narrativa • Apr 08
EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds
Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.Actualización de narrativa • Mar 25
EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality
Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.Recent updates
Actualización de narrativa • May 10
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Euroapi's analyst price target has shifted lower from about €3.08 to €2.00, with analysts pointing to Deutsche Bank's recent cut in its target to €1, along with updated views on revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts may see the lower price target range, now clustering around €1 to €2, as setting a more conservative bar for execution, which can reduce the risk of further valuation resets if expectations are now better aligned with current fundamentals.Actualización de narrativa • Apr 22
EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings
Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.Actualización de narrativa • Apr 08
EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds
Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.Actualización de narrativa • Mar 25
EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality
Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.Actualización de narrativa • Mar 10
EAPI: Weaker 2025 Guidance Will Pressure Margins And Future Earnings Quality
Analysts have cut their Euroapi price target from €2 to €1, reflecting updated assumptions that now factor in lower revenue growth expectations, much slimmer profit margins, and a significantly higher future P/E multiple. Analyst Commentary Recent price target revisions point to a cautious stance from bearish analysts, who appear focused on execution risks and the implications for Euroapi's valuation.Actualización de narrativa • Feb 24
EAPI: Lower 2025 Guidance And Reduced Multiple Will Shape Return Profile
Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing updated assumptions on modest revenue growth, slightly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent research points to a more cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.Actualización de narrativa • Feb 09
EAPI: Lower 2025 Outlook And Cautious Stance Will Shape Return Profile
Analysts have lowered their price target on Euroapi from €2.50 to €2, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that collectively suggest a more cautious valuation stance. Analyst Commentary Bearish analysts have recently cut their price target on Euroapi from €2.50 to €2.Actualización de narrativa • Jan 25
EAPI: Execution Risks And Lower Outlook Will Shape Future Return Profile
Narrative update Analysts have trimmed their price target on Euroapi by €0.50 to €2.00, citing updated assumptions on revenue growth, profit margins and forward P/E that keep their stance cautious on the shares. Analyst Commentary Recent research has reinforced a cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.00.Actualización de narrativa • Jan 10
EAPI: Lower Profitability Assumptions And New Partnership Will Shape Future Returns
Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing softer assumptions around revenue growth, profit margins and a higher future P/E multiple as the key drivers of the reset. Analyst Commentary Bearish analysts are signalling a cautious stance on Euroapi by aligning around a lower price target of €2, narrowed from €2.50.Actualización de narrativa • Dec 19
EAPI: Higher Discount Rate Will Outweigh Benefits From New Corticosteroid Partnership
Analysts have slightly reduced their Euroapi price target, reflecting a modest reassessment of fair value. This adjustment accounts for a higher discount rate, even as long term profit margin assumptions edge up and revenue declines appear marginally less severe.Artículo de análisis • Dec 18
Calculating The Intrinsic Value Of Euroapi S.A. (EPA:EAPI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €2.68 Euroapi's €2.40 share...Artículo de análisis • Dec 18
Euroapi S.A. (EPA:EAPI) Not Doing Enough For Some Investors As Its Shares Slump 26%
Euroapi S.A. ( EPA:EAPI ) shareholders that were waiting for something to happen have been dealt a blow with a 26...Artículo de análisis • Oct 03
Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Artículo de análisis • Aug 02
Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates
It's been a mediocre week for Euroapi S.A. ( EPA:EAPI ) shareholders, with the stock dropping 12% to €2.79 in the week...
Nueva narrativa • Mar 31
Capacity Expansion And Efficiency Improvements Will Shape Future Success
Euroapi focuses on high-margin differentiated APIs and CDMO services to boost sustainable revenue and profit margins through strategic project expansions.Artículo de análisis • Mar 06
Analyst Estimates: Here's What Brokers Think Of Euroapi S.A. (EPA:EAPI) After Its Annual Report
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...Artículo de análisis • Oct 04
Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price
Key Insights The projected fair value for Euroapi is €2.62 based on 2 Stage Free Cash Flow to Equity Current share...Artículo de análisis • Jul 29
There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise
Euroapi S.A. ( EPA:EAPI ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...Artículo de análisis • May 24
Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Those holding Euroapi S.A. ( EPA:EAPI ) shares would be relieved that the share price has rebounded 29% in the last...Artículo de análisis • Apr 10
Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Mar 03
Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding
The Euroapi S.A. ( EPA:EAPI ) share price has fared very poorly over the last month, falling by a substantial 31%. For...Artículo de análisis • Mar 02
Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a major selloff in Euroapi S.A. ( EPA:EAPI ) shares in the week since it released its yearly report, with...Artículo de análisis • Dec 21
A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €5.03 With €5.47 share price...Artículo de análisis • Aug 04
Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...Artículo de análisis • Aug 02
Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €24.50 Euroapi is estimated to...Artículo de análisis • Jun 16
Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity
When close to half the companies operating in the Pharmaceuticals industry in France have price-to-sales ratios (or...Artículo de análisis • Jan 25
An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued
Key Insights Euroapi's estimated fair value is €21.9 based on 2 Stage Free Cash Flow to Equity Current share price of...Rentabilidad de los accionistas
| EAPI | FR Pharmaceuticals | Mercado FR | |
|---|---|---|---|
| 7D | 3.3% | 2.9% | 2.0% |
| 1Y | -44.2% | -10.6% | 1.3% |
Rentabilidad vs. Industria: Los resultados de EAPI fueron inferiores a los de la industria French Pharmaceuticals, que obtuvo un rendimiento del -10.6% el año pasado.
Rentabilidad vs. Mercado: EAPI obtuvo unos resultados inferiores a los del mercado French, que fueron del 1.3% el año pasado.
Volatilidad de los precios
| EAPI volatility | |
|---|---|
| EAPI Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in FR Market | 10.6% |
| 10% least volatile stocks in FR Market | 3.0% |
Precio estable de las acciones: El precio de las acciones de EAPI ha sido volátil durante los últimos 3 meses en comparación con el mercado French.
Volatilidad a lo largo del tiempo: La volatilidad semanal de EAPI(9%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de French.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2020 | 2,961 | David Seignolle | www.euroapi.com/en |
Euroapi S.A. desarrolla, fabrica, comercializa y distribuye ingredientes farmacéuticos activos e intermedios utilizados en la formulación de medicamentos para uso humano y veterinario. La empresa proporciona una organización de fabricación de desarrollo por contrato para diferentes clases de mareas que utiliza la química de fase sólida; ingeniería de partículas; fermentación microbiana; síntesis de pequeñas moléculas; prostaglandinas; esteroides y hormonas; y opiáceos y sustancias controladas, así como lípidos. Ofrece sus productos a empresas farmacéuticas, fabricantes de medicamentos genéricos, fabricantes de productos de salud animal, empresas de salud del consumidor, nutrición y productos cosméticos, empresas de biotecnología y empresas de distribución, así como a organizaciones de desarrollo y fabricación por contrato.
Resumen de fundamentos de Euroapi S.A.
| Estadísticas fundamentales de EAPI | |
|---|---|
| Capitalización bursátil | €142.78m |
| Beneficios(TTM) | -€211.20m |
| Ingresos (TTM) | €852.60m |
0.2x
Ratio precio-ventas (PS)-0.7x
Ratio precio-beneficio (PE)¿Está EAPI sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de EAPI | |
|---|---|
| Ingresos | €852.60m |
| Coste de los ingresos | €707.70m |
| Beneficio bruto | €144.90m |
| Otros gastos | €356.10m |
| Beneficios | -€211.20m |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
Jul 28, 2026
| Beneficios por acción (BPA) | -2.22 |
| Margen bruto | 17.00% |
| Margen de beneficio neto | -24.77% |
| Ratio deuda/patrimonio | 5.8% |
¿Cómo se ha desempeñado EAPI a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/24 18:39 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Euroapi S.A. está cubierta por 11 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Justin Steven Smith | Bernstein |
| Patrick Andrew Wood | BofA Global Research |
| Falko Friedrichs | Deutsche Bank |